<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Rajendra A</submitter><journal>Blood cancer journal</journal><pagination>143</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12378385</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.</pubmed_title><pmcid>PMC12378385</pmcid><pubmed_authors>Rajendra A</pubmed_authors><pubmed_authors>Davidson MB</pubmed_authors><pubmed_authors>Gupta V</pubmed_authors><pubmed_authors>Schimmer AD</pubmed_authors><pubmed_authors>Perusini MA</pubmed_authors><pubmed_authors>Richard-Carpentier G</pubmed_authors><pubmed_authors>Smith E</pubmed_authors><pubmed_authors>Atenafu EG</pubmed_authors><pubmed_authors>Tang K</pubmed_authors><pubmed_authors>Yee K</pubmed_authors><pubmed_authors>Schuh AC</pubmed_authors><pubmed_authors>Maze D</pubmed_authors><pubmed_authors>Minden MD</pubmed_authors><pubmed_authors>Sibai H</pubmed_authors><pubmed_authors>Bankar A</pubmed_authors><pubmed_authors>Chan S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.</name><description/><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-10T01:48:51.461Z</modification><creation>2026-04-08T01:25:00.605Z</creation></dates><accession>S-EPMC12378385</accession><cross_references><pubmed>40854875</pubmed><doi>10.1038/s41408-025-01353-2</doi></cross_references></HashMap>